
|Articles|August 18, 2016
EndoPredict vs Oncotype DX for Predicting Breast Cancer Recurrence
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
3
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5



















































































